K. Legg

TL;DR: IAVI-006 was the first large randomised, double-blinded, placebo-controlled Phase I clinical trial to systematically investigate the prime-boost strategy for induction of HIV-1 specific CD8+ cytotoxic T-lymphocytes (CTL) in a factorial trial design using priming with 0.5 mg or 2 mg of pTHr.

TL;DR: The significantly greater T cell responses in HESNs, including in two who were homozygous for CCR5Δ32, demonstrates that HIV-1-specific Tcell responses can be induced or augmented by exposure to HIV- 1 without infection.

TL;DR: Mechanisms associated with participation in two related phase II PHV trials were studied and key recommendations to assist PHV trial teams who are planning future studies were devised.

TL;DR: Employment of a risk quantification model facilitated quantification and comparison of HIV acquisition risk across two disparate HIV serodiscordant couple cohorts.

TL;DR: Guimaraes-Walkera et al. as discussed by the authors presented lessons from IAVI-006, a Phase I clinical trial to evaluate the afety and immunogenicity of the pTHr.